Table 1 Glypican-3 and alpha-fetoprotein levels in pretreatment hepatoblastoma patients.
Glypican-3 | p-value | Alpha-fetoprotein | p-value | |
|---|---|---|---|---|
Median (rang), ng/ml | Median (rang), ng/ml | |||
Age, yr | 0.141 | 0.526 | ||
<3 | 2.3 (0.08–31.19) | 210,000 (64.6–1480,000) | ||
≥3 | 1.56 (0–13.65) | 34,200 (1540–785,000) | ||
Sex | 0.860 | 0.916 | ||
Male | 1.82 (0–31.19) | 188,000 (1540–1280,000) | ||
Female | 2.30 (0.08–23.13) | 93,700 (64.6–1480,000) | ||
Tumor size | 0.533 | 0.071 | ||
<10 cm | 1.3 (0.46–31.19) | 71.700 (64.6–514,000) | ||
≥10 cm | 2.3 (0–23.13) | 243,000 (1540–1480,000) | ||
PRETEXT stage | 0.503 | 0.062 | ||
I/II | 1.56 (0.46–11.82) | 22,200 (64.6–315,000) | ||
III/IV | 2.04 (0–31.19) | 210,000 (1540–1480,000) | ||
Lymphovascular invasion | 0.291 | 0.644 | ||
Absence | 4.34 (0.08–31.19) | 199,000 (64.6–1480,000) | ||
Presence | 1.5 (0–13.65) | 87,700 (1540–1280,000) | ||
Metastasis | 0.268 | 0.307 | ||
Absence | 1.43 (0–31.19) | 199,000 (64.6–1480,000) | ||
Presence | 2.70 (2.04–13.65) | 63,950 (1540–243,000) |
